Company news

Biogen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotrophic Lateral Sclerosis

March 27, 2022

Biogen Announces Peer-Reviewed Publication of ADUHELM® Phase 3 EMERGE and ENGAGE Data in The Journal of Prevention of Alzheimer’s Disease

March 15, 2022

Biogen and Eisai amend collaboration agreements on Alzheimer’s disease treatments

March 13, 2022

Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA® (Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis

February 6, 2022

Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody

January 31, 2022

Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors

January 30, 2022

Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion

January 26, 2022

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

January 3, 2022

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

December 19, 2021

Update on Regulatory Submission for Aducanumab in the European Union

December 16, 2021

Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience

December 13, 2021

Update on Regulatory Review of Aducanumab in the European Union

November 16, 2021

The European Commission Grants Marketing Authorization for VUMERITY® (diroximel fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis

November 15, 2021

Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development

November 14, 2021

Biogen Announces Late Breakers and Additional New Data Presentations at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting

November 2, 2021

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

October 16, 2021

Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience

September 20, 2021

FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)

September 19, 2021

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

September 15, 2021

Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)

September 14, 2021

Biogen Announces Results from Phase 3b NOVA Study Evaluating Every Six-Week Dosing with Natalizumab in Relapsing-Remitting Multiple Sclerosis

August 1, 2021

Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021

July 28, 2021

Biogen and Eisai Announce ADUHELM™ (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

July 25, 2021

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

July 11, 2021

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

July 7, 2021

Eisai And Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation For Lecanemab (BAN2401), An Anti-Amyloid Beta Protofibril Antibody For The Treatment Of Alzheimer's Disease

June 22, 2021

Biogen Announces First Patient Dosed in Phase 3 Systemic Lupus Erythematosus Study

June 16, 2021

Biogen Announces Topline Results From Phase 2 Study of Gosuranemab, an Anti-Tau Antibody, for Alzheimer’s Disease

June 15, 2021

Biogen Announces Topline Results from Phase 3 Gene Therapy Study in Choroideremia

June 13, 2021

Biogen Announces Investor Day on September 21, 2021

June 9, 2021

Biogen and Eisai launch multiple initiatives to help patients with Alzheimer’s disease access ADUHELM™

June 6, 2021

Biogen and Bio-Thera Announce Positive Results From Phase 3 Study of BAT1806, a Proposed Biosimilar Referencing Actemra® (Tocilizumab)

May 31, 2021

Biogen and Ginkgo Bioworks Announce Collaboration and License Agreement to Develop Novel Gene Therapy Manufacturing Platform

May 20, 2021

Swissmedic Grants Good Manufacturing Practice Multi-Product License to Biogen Biologics Facility in Solothurn, Switzerland

May 19, 2021

Biogen Announces Topline Results From Phase 2/3 Gene Therapy Study for XLRP

May 13, 2021

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

May 12, 2021

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

May 11, 2021

Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

May 9, 2021

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

April 27, 2021

← Newer news releases

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 55 decks. Every deck is listed under its year.